Generic drugs approved by FDA (through September 2008) including nisoldipine extended-release tablets and divalproex delayed-release tablets
Nisoldipine extended-release tablets, 20, 30, and 40 mg (equiv to Sular ER tablets) MYLAN
Divalproex delayed-release tablets, 125, 250, and 500 mg (equiv to Depakote delayed-release tablets) DR. REDDY'S, GENPHARM, LUPIN, NU-PHARM, SANDOZ, SUN, TEVA, UPSHER-SMITH
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen